| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
|
Medicine details |
|
| Medicine name | gemtuzumab ozogamicin (Mylotarg®) |
| Formulation | 5 mg powder for concentrate for solution for infusion |
| Reference number | 2679 |
| Indication | Combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia, except acute promyelocytic leukaemia |
| Company | Pfizer Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/04/2018 |
| NICE guidance | TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |